 Multiple Myeloma
"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 2 | 0 | 2 | | 2005 | 4 | 0 | 4 | | 2007 | 3 | 0 | 3 | | 2008 | 2 | 1 | 3 | | 2009 | 2 | 0 | 2 | | 2010 | 4 | 0 | 4 | | 2011 | 9 | 1 | 10 | | 2012 | 1 | 0 | 1 | | 2013 | 4 | 1 | 5 | | 2014 | 11 | 0 | 11 | | 2015 | 13 | 0 | 13 | | 2016 | 10 | 0 | 10 | | 2017 | 13 | 2 | 15 | | 2018 | 15 | 1 | 16 | | 2019 | 19 | 0 | 19 | | 2020 | 24 | 1 | 25 | | 2021 | 24 | 1 | 25 | | 2022 | 18 | 0 | 18 | | 2023 | 19 | 0 | 19 | | 2024 | 15 | 0 | 15 | | 2025 | 20 | 0 | 20 | | 2026 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ. Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. Blood Cancer J. 2026 Mar 20; 16(1).
-
Ohlstrom DJ, Pilcher WC, Michaud ME, Acharya C, Satpathy S, Gonzalez-Kozlova E, Jayasinghe RG, Ferguson K, Mumme HL, Nanda S, Song Y, Mantrala S, Karagkouni D, Schulman J, Pabustan N, Vieira Dos Santos J, Sherbenou DW, Keats JJ, Gout AM, Foltz S, Lagana A, Kourelis T, Vij R, Dhodapkar MV, Avigan D, Cho HJ, Baughn LB, Nooka AK, Lonial S, Kumar S, Samur MK, Vlachos IS, Ding L, Gnjatic S, Mulligan G, Bhasin MK. Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma. Blood Cancer Discov. 2026 Mar 04; 7(2):266-286.
-
Cardus O, Mañé Pujol J, de Daniel A, Moreno DF, Oliveira TGM, Battram AM, Salsench SV, Perez-Amill L, Llobregat H, Carpio Mármol J, Martin-Antonio B, Oliver-Caldes A, Munárriz D, Juan M, Urbano-Ispizua A, Rodríguez-Lobato LG, Fernández de Larrea C. Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. J Immunother Cancer. 2026 Mar 03; 14(3).
-
Arnold KD, Ong KL, Ravi G, Wessel MC, Davies FE, Costa LJ, Deshpande A, Morgan GJ, Birmann BM, Brown EE. Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma. Blood Adv. 2026 Jan 27; 10(2):439-451.
-
Moreno-Castaño AB, Fernández S, Brillembourg H, Iraola G, Moreno DF, Ventosa-Capell H, Martinez-Sanchez J, De Moner B, Molina P, Ramos A, Palomo M, Gómez-Ramírez P, Ortiz-Maldonado V, Martínez-Cibrián N, Delgado J, Oliver-Caldés A, Fernández de Larrea C, Salas MQ, Urbano Á, Téllez A, Nicolás JM, Juan M, González-Navarro A, Penack O, Escolar G, Carreras E, Fernández-Avilés F, Castro P, Diaz-Ricart M. m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis. Front Immunol. 2025; 16:1664788.
-
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson TJ, Rosenberg A, Sarosiek SR, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Ye JC, Kovach E, Kumar R. Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Jan; 24(1).
-
Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortüm KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. J Clin Oncol. 2026 Jan 20; 44(3):164-175.
-
Dimopoulos MA, Lonial S, Chng WJ, Iida S, Mateos MV, Morgan GJ, Li C, Byrne C, Suryanarayan K, Labotka R, Rajkumar SV. Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma. Blood Cancer J. 2025 Dec 04; 16(1):15.
-
Beer SA, Cairns DA, Pawlyn C, Holroyd A, Ferris E, Cook G, Drayson M, Boyd K, Proszek P, Davies FE, de Tute R, Jenner M, Morgan GJ, Owen R, Hubank M, Houlston R, Jackson G, Kaiser MF. Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. Blood. 2025 Nov 27; 146(22):2670-2680.
-
Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees M, Costello P, Vazquez Martinez M, Pasvolsky O, Wagner C, Davis JA, Castaneda Puglianini O, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo R, Freeman C, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa M, Midha S, Alsina M, Sborov D, Patel K, Lin Y, Ferreri C, Gagelmann N, Kumar A, Hansen D, Cowan A, Costa LJ, Merz M, Sidana S. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct 23; 146(17):2063-2072.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|